Key Takeaways
- Strong quarter, capacity-led growth story: Total income grew 27% YoY and 10.5% QoQ, but the core narrative is the imminent Jammu plant commercialization that management believes will double revenue in three years.
- Jammu is the thesis: The greenfield facility commercializes in Q2, targets ₹800–₹900 crores at 40–50% utilization over 3–4 years, and carries margin improvement from year two onward.
- Margins held steady with a caveat: EBITDA margin at 15.1% sits inside the 14–16% guided range, though down from 16.7% QoQ on seasonality; management expects margins to remain at similar levels.
- API pricing finding a floor: After 3–4 years of post-COVID decline, API prices have stabilized for the last two quarters, setting up volume-led revenue growth from next quarter.
- What to watch next quarter: Whether Jammu commercialization stays on the September timeline, the pace of volume growth now that API pricing has normalized, and any margin trajectory update as the new plant begins contributing.
Jammu Expansion: The Growth Engine
- Facility scope: Four independent blocks covering cephalosporin, penicillin, penum and BFS; adds oral solids, dry powder injectables, dry syrup, BFS, large volume parenteral and respiratory respules to the product basket.
- Commercialization path: Cephalosporin block goes first via tech transfer route, commercializing from September; revenue contribution begins Q3 FY25, with the first two quarters expected to be difficult.
- Revenue ambition: At 40–50% utilization, Jammu can generate ₹800–₹900 crores over 3–4 years, with 70–80% of that in external CDMO sales and the rest through Univentis Medicare, the trade arm.
- FY26 trajectory: Management anticipates better than ₹200–₹300 crores from Jammu next year, with a clear runway set after the initial ramp.
- International lag: International sales from Jammu will take 1–2 years to materialize due to dossier filing requirements; near-term revenue is domestic CDMO.
- Capex largely done: Most Jammu capex is already spent; going forward, only maintenance capex at 3–4% of gross block plus ₹10–₹15 crores this year on the new Panchkula R&D center.
Lohariwala: "With the help of Jammu plant, we are feeling that again we will double our revenue and bottom-line numbers to double in the next 3 years."
CDMO Business & Schedule M Opportunity
- Domestic CDMO model: Innova develops its own generic products and offers them on a P2P basis to domestic pharmaceutical companies, distinct from international CDMO services sold to innovators.
- Schedule M as a catalyst: Revised regulations require capital investment, science-based documentation and practice changes; management sees this as a consolidation opportunity that will funnel business toward compliant, scaled players like Innova.
- Inquiry pipeline: Incremental inquiries are coming through a continuous process, with some specifically driven by consolidation effects from Schedule M compliance requirements.
- CDMO share stable: The segment is expected to remain at 56–58% of the business mix even after Jammu ramps up, since Jammu output will flow to both CDMO and trade generics in similar proportions.
- Pricing normalization: API price declines have halted for two quarters, and with the base normalizing, volume growth should start reflecting in revenue numbers from next quarter.
Lohariwala: "We see it as a great opportunity in the CDMO space not only for the Innova for all the companies. Those who will comply with the regulation will go ahead into the curve and will attract the good business."
Capacity & Utilization
- Group utilization at ~52%: Oral solid dosage utilization is lower at ~45% because it is a complex dosage form with wide manufacturer availability, while oral liquids and injectables are less complex and run higher.
- Baddi constraints: Two of three blocks in the existing Baddi facilities are at high utilization (70–85%); only the general block expanded in 2017 and 2021 has spare capacity in oral solid dosages, limiting organic growth to early teens.
- Growth corrected: An analyst estimated 20–25% growth ex-Jammu; management clarified that capacity constraints cap Baddi at early-teen growth, with most incremental growth coming from Jammu.
- Post-Jammu footprint: Five facilities with nine independent manufacturing blocks, extending the product range into BFS, large volume parenteral, respiratory respules, ointments, dry powder injectables, dry syrup and liquid orals.
Business Segments & Mix
- Trade generics: Started in 2016, now covers almost pan-India with focus on areas of lesser sale or less deep concentration; expected to maintain its 17% share of the business as the company doubles in three years.
- Domestic branded generics: Growing at a rapid pace with focus on remote locations and product basket expansion; management aims to sustain 30%+ CAGR.
- Gross margin drivers: 300–400 bps improvement over the last 3–4 quarters came from product mix, since domestic and international branded generics carry better margins than CDMO; business composition is expected to remain broadly stable.
- Sharon Bio-Medicine: Fourth quarter consolidated into the P&L; focus is on regulated market CDMO sales with new products under development.
- Segment margin opacity: Management declined to disclose EBITDA margins by segment, stating they are tracked only at the entity level.
API Sourcing & Input Costs
- Domestic shift underway: 70–80% of API is currently sourced domestically, and the trend is expected to increase as PLI schemes and China substitution take effect.
- Acute vs chronic parity: API pricing trends are more or less the same across acute and chronic categories for the company.
- Historical sourcing undisclosed: Management did not provide a specific domestic sourcing percentage from 1–2 years ago, offering only a forward-looking statement on the PLI-driven trend.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue CAGR | Maintain 35% CAGR | Next 3–4 years |
| Jammu commercialization | Cephalosporin block via tech transfer | September 2024 (Q2 FY25) |
| Jammu revenue contribution | Revenue begins; first two quarters difficult | Q3 FY25 |
| Jammu margin improvement | Noticeable from second year | FY27 onwards |
| Jammu revenue target | ₹800–₹900 crores at 40–50% utilization | 3–4 years |
| Jammu FY26 revenue | Better than ₹200–₹300 crores | FY26 |
| Revenue doubling | Double revenue and bottom-line numbers | Next 3 years |
| Domestic branded generics CAGR | Maintain 30%+ | Ongoing |
| CDMO business share | Remain at 56–58% | Future |
| Trade generics share | Maintain 17% constituent | As company doubles in 3 years |
| Capex | Maintenance capex at 3–4% of gross block; R&D capex ₹10–₹15 crores this year | Until next manufacturing facility planned |
| Blended growth FY25 | Better than 12–15% (Jammu data added) | FY25 |
| Margins | Remain at similar level | Ongoing |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Total income | ₹296 cr, +27% YoY and +10.5% QoQ |
| EBITDA | ₹44 cr, +37% YoY and +1% QoQ |
| EBITDA margin | 15.1%, vs 13.9% in Q1 FY24 and 16.7% in Q4 FY24 |
| PAT | ₹29.5 cr, +68% YoY and +3% QoQ |
| PAT margin | 10%, vs 7.5% in Q1 FY24 and 10.9% in Q4 FY24 |
| Revenue CAGR (past 3-4 years) | 35% |
| Revenue doubling expectation | Double in next 3 years, with help of Jammu plant |
| CDMO share of total income | 57%, expected to remain 56%-58% in future |
| Domestic branded generics share | 17% |
| International branded generics share | 11% |
| Sharon share | 15% |
| Group capacity utilization | ~52% |
| Tablet/capsule capacity utilization | ~45% |
| Cephalosporin and original block utilization | 70% to 80%-85% |
| Jammu plant capex | ~₹450 cr |
| Jammu plant revenue potential (at 40%-50% utilization) | ₹800-₹900 cr in 3-4 years |
| Jammu plant commercialization timeline | Q2 FY25, revenue from Q3 FY25 |
| API domestic sourcing | 70%-80% |
| Branded generics sales force | ~300 persons |
| R&D capex (Panchkula) | ₹10-₹15 cr total expenditure this year |
| Maintenance capex | 3%-4% of gross block |